Dynavax Business Model Canvas
Dynavax Business Model Canvas: Vaccine Strategy, Revenue & Templates in One Download
Unlock the full strategic blueprint behind Dynavax’s business model—this concise Business Model Canvas maps core activities, partners, and revenue levers that drive its vaccine-focused growth.
Perfect for investors, advisors, and founders, the downloadable Canvas breaks down value propositions, cost structure, and market positioning for immediate analysis.
Purchase the full Word/Excel kit to access all nine blocks with company-specific insights and ready-to-use templates for strategic planning.
Partnerships
Strategic Adjuvant Collaborators
Dynavax partners with global vaccine developers to incorporate its CpG 1018 adjuvant into candidates, including a 2024/25 supply and development deal with India’s Biological E and a 2023 commercial pact with Valneva for enhanced hepatitis and COVID vaccine formulations.
Global Distribution Partners
Dynavax partners with local distributors to supply HEPLISAV-B and other vaccines, outsourcing cold-chain logistics, regulatory filings, and customs to firms that cover 45+ countries; this avoided an estimated $40–60M in fixed global infrastructure spend through 2024 while supporting 22% annual international shipment growth in 2023–2024.
Contract Manufacturing Organizations
Dynavax uses third-party Contract Manufacturing Organizations (CMOs) to produce active pharmaceutical ingredients and provide fill-finish services for HEPLISAV-B; in 2024 CMOs supported annualized capacity near 10 million doses, enabling variable supply to match demand spikes. Relying on audited, FDA-inspected CMOs ensures GMP compliance and global regulatory alignment, reducing production risk and capital outlay for Dynavax.
Research and Academic Institutions
Dynavax partners with top universities (e.g., UCSF, University of Oxford collaborations reported in 2024) to co-develop TLR ligand applications, funding joint labs and supplying adjuvants for preclinical studies—these ties accelerated 3+ candidate programs into IND-enabling studies by 2025.
- Academic collaborations cut early-stage cost, ~20% of preclinical budget saved (2023–2025)
- Supported 3 IND-enabling programs by 2025
- Access to >200 immunology specialists and core labs
Government and Public Health Agencies
Dynavax partners with CDC and state health departments to supply clinical and post-market data that led to ACIP (Advisory Committee on Immunization Practices) recommendation for HEPLISAV-B in 2018 and supported uptake—U.S. vaccine doses sold ~$37M in 2024, aiding inclusion in adult immunization schedules.
- Data sharing drove ACIP recommendation (2018)
- State-level adoption affects reimbursement and distribution
- 2024 U.S. HEPLISAV-B sales ≈ $37M, public programs key
Dynavax leverages CMOs, CpG partnerships to scale 10M doses, cut $40–60M, $37M US sales
Dynavax outsources manufacturing and distribution, supplies CpG 1018 to partners (Biological E 2024/25, Valneva 2023), and funds academic R&D; CMOs enabled ~10M dose capacity (2024), saved ~$40–60M in infrastructure to 2024, supported 22% intl shipment growth (2023–24), and U.S. HEPLISAV-B sales ≈ $37M (2024).
| Partnership | Key 2024–25 Data |
|---|---|
| CMOs | ~10M dose capacity |
| Distribution | 22% intl growth; $40–60M cost avoided |
| Commercial | HEPLISAV-B US sales $37M |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for Dynavax detailing customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and customer relationships—aligned to its vaccine development, commercialization, and licensing strategy and ideal for investor presentations and strategic planning.
Customizable Excel Spreadsheet
High-level view of Dynavax’s business model as a pain-point reliever—editable canvas highlighting vaccine development, commercial partnerships, and regulatory pathways to quickly pinpoint strategic gaps and streamline go-to-market decisions.
Activities
Vaccine Research and Development
Dynavax centers R&D on advancing its clinical pipeline for shingles, Tdap, and other infectious diseases, running multiple Phase 2/3 trials and spending about $140M on R&D in FY2024 to prove safety and efficacy for FDA and EMA filings.
Commercialization of HEPLISAV-B
Dynavax concentrates on commercialization of HEPLISAV-B, deploying a specialized sales force to grow adult-segment share across health systems, retail pharmacies, and government clinics; HEPLISAV-B drove $131.7 million in 2024 U.S. revenue, making it the company’s primary revenue driver. The team emphasizes account-level contracting and provider education to expand adult vaccination rates—U.S. adult hepatitis B vaccine market estimated at ~$450 million in 2024, with Dynavax holding ~29%.
Adjuvant Platform Optimization
Dynavax actively manages its CpG 1018 adjuvant platform to support internal vaccines and >20 partner programs, refining manufacturing scale-up and GMP yields (targeting >90% batch success) to cut COGS and speed time-to-clinic. The company runs cross-vaccine immunogenicity and stability studies—57 trials or assays since 2018—to demonstrate efficacy across platforms, preserving technical lead and securing multi-year licensing revenue potential.
Regulatory Affairs and Compliance
Dynavax spends continuous resources navigating FDA and international approvals, filing Biologics License Applications and IND/CTA submissions while running post-market surveillance for HEPLISAV-B; in 2024 the company reported R&D and regulatory expenses of $72.3M, reflecting this ongoing effort.
Maintaining GMP compliance and timely safety reporting underpins supply stability and revenue recognition, with manufacturing audits and adverse event reporting processes tied to contract manufacturers and BLA obligations.
- Files: IND/CTA, BLA submissions and supplements
- 2024 regulatory/R&D spend: $72.3M (company FY2024)
- Key product: HEPLISAV-B post-market surveillance active
- GMP audits & safety reporting mandatory for contract manufacturers
Strategic Business Development
Dynavax pursues strategic business development to secure licensing, partnership, and acquisition deals that diversify its vaccine pipeline and generate milestone and royalty revenue; in 2024 the company reported collaboration revenue of $12.4M, underscoring this stream.
This planning directs capital between internal R&D—$120M cash and equivalents at Q3 2025—and external deals to maximize ROI and steady cash flow.
- Targets: licensing, M&A, partnerships
- 2024 collaboration revenue: $12.4M
- Q3 2025 cash: $120M
- Goal: steady milestone/royalty stream
Dynavax: HEPLISAV-B leader (29%); heavy R&D ($140M) and CpG 1018 scale-up, $120M cash
Dynavax runs clinical R&D (Phase 2/3) and spent ~$140M R&D FY2024 to advance vaccines; commercializes HEPLISAV-B ($131.7M US rev 2024; ~29% market share of ~$450M US adult HBV market); manages CpG 1018 adjuvant scale-up (>20 partner programs) and regulatory/GMP activities (regulatory/R&D $72.3M 2024); 2024 collaboration revenue $12.4M; Q3 2025 cash $120M.
| Metric | Value |
|---|---|
| R&D spend FY2024 | $140M |
| Regulatory/R&D 2024 | $72.3M |
| HEPLISAV-B US revenue 2024 | $131.7M |
| US adult HBV market 2024 | $450M |
| Dynavax share | ~29% |
| Collaboration revenue 2024 | $12.4M |
| Q3 2025 cash | $120M |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the authentic Dynavax Business Model Canvas — not a mockup or sample — and it's the exact file you'll receive after purchase; when you complete your order, you'll get full access to this same professional, ready-to-use document in editable Word and Excel formats.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Dynavax Business Model Canvas: Vaccine Strategy, Revenue & Templates in One Download
Unlock the full strategic blueprint behind Dynavax’s business model—this concise Business Model Canvas maps core activities, partners, and revenue levers that drive its vaccine-focused growth.
Perfect for investors, advisors, and founders, the downloadable Canvas breaks down value propositions, cost structure, and market positioning for immediate analysis.
Purchase the full Word/Excel kit to access all nine blocks with company-specific insights and ready-to-use templates for strategic planning.
Partnerships
Strategic Adjuvant Collaborators
Dynavax partners with global vaccine developers to incorporate its CpG 1018 adjuvant into candidates, including a 2024/25 supply and development deal with India’s Biological E and a 2023 commercial pact with Valneva for enhanced hepatitis and COVID vaccine formulations.
Global Distribution Partners
Dynavax partners with local distributors to supply HEPLISAV-B and other vaccines, outsourcing cold-chain logistics, regulatory filings, and customs to firms that cover 45+ countries; this avoided an estimated $40–60M in fixed global infrastructure spend through 2024 while supporting 22% annual international shipment growth in 2023–2024.
Contract Manufacturing Organizations
Dynavax uses third-party Contract Manufacturing Organizations (CMOs) to produce active pharmaceutical ingredients and provide fill-finish services for HEPLISAV-B; in 2024 CMOs supported annualized capacity near 10 million doses, enabling variable supply to match demand spikes. Relying on audited, FDA-inspected CMOs ensures GMP compliance and global regulatory alignment, reducing production risk and capital outlay for Dynavax.
Research and Academic Institutions
Dynavax partners with top universities (e.g., UCSF, University of Oxford collaborations reported in 2024) to co-develop TLR ligand applications, funding joint labs and supplying adjuvants for preclinical studies—these ties accelerated 3+ candidate programs into IND-enabling studies by 2025.
- Academic collaborations cut early-stage cost, ~20% of preclinical budget saved (2023–2025)
- Supported 3 IND-enabling programs by 2025
- Access to >200 immunology specialists and core labs
Government and Public Health Agencies
Dynavax partners with CDC and state health departments to supply clinical and post-market data that led to ACIP (Advisory Committee on Immunization Practices) recommendation for HEPLISAV-B in 2018 and supported uptake—U.S. vaccine doses sold ~$37M in 2024, aiding inclusion in adult immunization schedules.
- Data sharing drove ACIP recommendation (2018)
- State-level adoption affects reimbursement and distribution
- 2024 U.S. HEPLISAV-B sales ≈ $37M, public programs key
Dynavax leverages CMOs, CpG partnerships to scale 10M doses, cut $40–60M, $37M US sales
Dynavax outsources manufacturing and distribution, supplies CpG 1018 to partners (Biological E 2024/25, Valneva 2023), and funds academic R&D; CMOs enabled ~10M dose capacity (2024), saved ~$40–60M in infrastructure to 2024, supported 22% intl shipment growth (2023–24), and U.S. HEPLISAV-B sales ≈ $37M (2024).
| Partnership | Key 2024–25 Data |
|---|---|
| CMOs | ~10M dose capacity |
| Distribution | 22% intl growth; $40–60M cost avoided |
| Commercial | HEPLISAV-B US sales $37M |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for Dynavax detailing customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and customer relationships—aligned to its vaccine development, commercialization, and licensing strategy and ideal for investor presentations and strategic planning.
Customizable Excel Spreadsheet
High-level view of Dynavax’s business model as a pain-point reliever—editable canvas highlighting vaccine development, commercial partnerships, and regulatory pathways to quickly pinpoint strategic gaps and streamline go-to-market decisions.
Activities
Vaccine Research and Development
Dynavax centers R&D on advancing its clinical pipeline for shingles, Tdap, and other infectious diseases, running multiple Phase 2/3 trials and spending about $140M on R&D in FY2024 to prove safety and efficacy for FDA and EMA filings.
Commercialization of HEPLISAV-B
Dynavax concentrates on commercialization of HEPLISAV-B, deploying a specialized sales force to grow adult-segment share across health systems, retail pharmacies, and government clinics; HEPLISAV-B drove $131.7 million in 2024 U.S. revenue, making it the company’s primary revenue driver. The team emphasizes account-level contracting and provider education to expand adult vaccination rates—U.S. adult hepatitis B vaccine market estimated at ~$450 million in 2024, with Dynavax holding ~29%.
Adjuvant Platform Optimization
Dynavax actively manages its CpG 1018 adjuvant platform to support internal vaccines and >20 partner programs, refining manufacturing scale-up and GMP yields (targeting >90% batch success) to cut COGS and speed time-to-clinic. The company runs cross-vaccine immunogenicity and stability studies—57 trials or assays since 2018—to demonstrate efficacy across platforms, preserving technical lead and securing multi-year licensing revenue potential.
Regulatory Affairs and Compliance
Dynavax spends continuous resources navigating FDA and international approvals, filing Biologics License Applications and IND/CTA submissions while running post-market surveillance for HEPLISAV-B; in 2024 the company reported R&D and regulatory expenses of $72.3M, reflecting this ongoing effort.
Maintaining GMP compliance and timely safety reporting underpins supply stability and revenue recognition, with manufacturing audits and adverse event reporting processes tied to contract manufacturers and BLA obligations.
- Files: IND/CTA, BLA submissions and supplements
- 2024 regulatory/R&D spend: $72.3M (company FY2024)
- Key product: HEPLISAV-B post-market surveillance active
- GMP audits & safety reporting mandatory for contract manufacturers
Strategic Business Development
Dynavax pursues strategic business development to secure licensing, partnership, and acquisition deals that diversify its vaccine pipeline and generate milestone and royalty revenue; in 2024 the company reported collaboration revenue of $12.4M, underscoring this stream.
This planning directs capital between internal R&D—$120M cash and equivalents at Q3 2025—and external deals to maximize ROI and steady cash flow.
- Targets: licensing, M&A, partnerships
- 2024 collaboration revenue: $12.4M
- Q3 2025 cash: $120M
- Goal: steady milestone/royalty stream
Dynavax: HEPLISAV-B leader (29%); heavy R&D ($140M) and CpG 1018 scale-up, $120M cash
Dynavax runs clinical R&D (Phase 2/3) and spent ~$140M R&D FY2024 to advance vaccines; commercializes HEPLISAV-B ($131.7M US rev 2024; ~29% market share of ~$450M US adult HBV market); manages CpG 1018 adjuvant scale-up (>20 partner programs) and regulatory/GMP activities (regulatory/R&D $72.3M 2024); 2024 collaboration revenue $12.4M; Q3 2025 cash $120M.
| Metric | Value |
|---|---|
| R&D spend FY2024 | $140M |
| Regulatory/R&D 2024 | $72.3M |
| HEPLISAV-B US revenue 2024 | $131.7M |
| US adult HBV market 2024 | $450M |
| Dynavax share | ~29% |
| Collaboration revenue 2024 | $12.4M |
| Q3 2025 cash | $120M |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the authentic Dynavax Business Model Canvas — not a mockup or sample — and it's the exact file you'll receive after purchase; when you complete your order, you'll get full access to this same professional, ready-to-use document in editable Word and Excel formats.
